Genentech’s Tecentriq and Avastin reduce the risk of disease worsening or death from RCC December 29, 2017Vol.40 No.11
Phase III study of venetoclax in combination with rituximab meets primary endpoint December 29, 2017Vol.40 No.11
Juno Therapeutics and Celgene release additional data from TRANSCEND trial December 29, 2017Vol.40 No.11
Pfizer’s talazoparib extends PFS in phase III trial in metastatic breast cancer December 29, 2017Vol.40 No.11
In Brief Proton Partners to build new cancer center at Thames Valley Science Park, UK December 16, 2017Vol.42 No.46
In Brief Neufeld named clinical director, physician-in-chief & EVP at St. Jude December 16, 2017Vol.42 No.46
